Dec 8, 2025 02:53AM Zai Lab gets three drugs renewed on China's national reimbursement list

Nov 6, 2025 07:18AM Zai Lab Limited (ZLAB) Misses Q3 EPS by 8c

Sep 3, 2025 10:48AM Zai Lab pauses regulatory filing for bemarituzumab after trial results

Sep 2, 2025 05:01AM Zai Lab receives Hong Kong approval for cervical cancer drug TIVDAK

Aug 24, 2025 07:11PM Jefferies Assumes Zai Lab (ZLAB) at Buy

Aug 19, 2025 07:31AM ZAI LAB receives china medical device designation for pancreatic cancer therapy

Aug 7, 2025 06:06AM Zai Lab Limited (ZLAB) Tops Q2 EPS by 37c ; Offers Guidance

Jun 30, 2025 01:07PM Zai Lab (ZLAB) PT Raised to $75 at Leerink Partners

Jun 30, 2025 09:06AM Zai Lab Limited (ZLAB) Announces Positive Topline Phase 3 Results for Bemarituzumab

Jun 3, 2025 07:05AM Cantor Fitzgerald Reiterates Overweight Rating on Zai Lab (ZLAB)

Jun 2, 2025 07:01AM Zai Lab Limited (ZLAB) Presents Positive Phase 1 Data for ZL-1310

May 19, 2025 07:02AM Zai Lab (ZLAB) Receives U.S. FDA Fast Track Designation for ZL-1310

May 8, 2025 06:10AM Zai Lab Limited (ZLAB) Tops Q1 EPS by 42c

Apr 25, 2025 01:13PM Zai Lab Limited (ZLAB) Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies

Apr 21, 2025 07:30AM Zai Lab Limited (ZLAB) Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Apr 15, 2025 06:50AM Cantor Fitzgerald Reiterates Overweight Rating on Zai Lab (ZLAB)

Apr 11, 2025 06:40AM Cantor Fitzgerald Reiterates Overweight Rating on Zai Lab (ZLAB)

Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald

Mar 27, 2025 07:33AM Cantor Fitzgerald Reiterates Overweight Rating on Zai Lab (ZLAB)

Mar 7, 2025 07:13AM Scotiabank Starts Zai Lab (ZLAB) at Sector Outperform

Mar 3, 2025 05:01AM Zai Lab Limited (ZLAB) and ResMed (RMD) Added to Goldman APAC Director's Cut Conviction List

Mar 3, 2025 04:25AM BofA Securities Downgrades Zai Lab (ZLAB) to Neutral

Feb 27, 2025 06:11AM Zai Lab Limited (ZLAB) Tops Q4 EPS by 65c ; Offers Guidance

Jan 22, 2025 11:16PM Zai Lab Limited (ZLAB) Receives Orphan Drug Designation from the U.S. FDA for ZL-1310

Jan 17, 2025 07:30AM Zai Lab (ZLAB) Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Jan 15, 2025 07:30AM Zai Lab Limited (ZLAB) Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial

Jan 10, 2025 07:32AM Zai Lab (ZLAB) and Vertex (VRTX) Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Dec 2, 2024 07:03AM Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields

Nov 13, 2024 04:13PM Zai Lab Limited (ZLAB) Announces Proposed $200M Share Offering

Nov 12, 2024 06:34AM Zai Lab Limited (ZLAB) Tops Q3 EPS by 73c

Nov 11, 2024 07:31AM Zai Lab Limited (ZLAB) and argenx (ARGX) Announce Approval of VYVGART Hytrulo

Oct 29, 2024 07:31AM Zai Lab (ZLAB) Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Oct 24, 2024 04:24PM Zai Lab (ZLAB) PT Raised to $70 at Citi

Sep 27, 2024 08:05AM Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares'

Aug 27, 2024 08:32AM Zai Lab (ZLAB) to Present Preliminary Data From Phase 1 Trial of ZL-1218

Aug 6, 2024 04:18PM Zai Lab Limited (ZLAB) Reports Q2 Loss of $0.82, Beats on Revenue

Jul 15, 2024 02:53PM Zai Lab (ZLAB) -Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers